Looking Ahead: Long-Term Implications of HIV Pre-Exposure Prophylaxis (PrEP) Treatment DecisionsPremiere Date: Tuesday, October 5, 2021
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, October 5, 2022
Note: Credit Is No Longer Available
|Onyema Ogbuagu, MBBCh, FACP, FIDSA
Associate Professor of Medicine (AIDS)
Director, Clinical Trials Program, Yale AIDS Program
Section of Infectious Diseases
Yale School of Medicine
New Haven, CT
Despite the effectiveness of pre-exposure prophylaxis (PrEP), uptake remains suboptimal, with potentially less than 10% of candidates using and adhering to prophylaxis. Transgender women face particularly unique challenges and barriers that may impact their uptake and adherence to PrEP. It is imperative that clinicians reinforce the safety and efficacy of PrEP and concomitant use of gender-affirming hormones in transgender women as well as integrate risk factors associated with decreased bone mineral density (BMD) into treatment decision-making for PrEP.
In this CMEO BriefCase, we will meet Christine, a transgender woman who has been taking emtricitabine/tenofovir disoproxil fumarate (F/TDF) for 5 years and has become concerned with the discussions on social media about PrEP and its interactions with feminizing hormone therapy. Expert faculty will discuss this case and how to apply clinical trial data to decision-making for patients who are taking PrEP.
At the end of this CE activity, participants should be able to:
- Apply clinical trial data and other available evidence to decision-making for the management of patients taking PrEP.
Supported by an educational grant from Gilead Sciences, Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists
CME Credit (Physicians):
Physicians (ACCME): CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Nurses (ANCC): This activity is designated for . contact hours.
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Ogbuagu reports that he receives grants from Gilead Sciences, Inc. He is on the speakers bureau for Gilead Sciences, Inc. He is a consultant for ViiV Healthcare.
Michael Franks, APRN, AGACNP-BC, FNP-BC, (Peer Reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).